8-K: Clever Leaves Reports 6% Revenue Increase for 2023, Driven by Cannabinoid Sales Growth

Clever Leaves saw a 6% revenue increase in 2023, fueled by a 39% jump in cannabinoid revenue, alongside significant cost reductions and the sale of its non-cannabinoid business.

Summary

• Clever Leaves reported a 6% increase in revenue for 2023, reaching $17.4 million, compared to $16.4 million in 2022.
• Cannabinoid revenue saw a substantial 39% increase, totaling $6.6 million for the year, up from $4.7 million in the previous year.
• The company achieved a 24% reduction in general and administrative expenses for the full year and a 26% reduction in Q4.
• Clever Leaves completed the sale of its non-cannabinoid herbal brands business on March 21, 2024, for $8.02 million, including $7.02 million in cash.
• The company's cash balance improved to $6.9 million at the end of 2023, compared to $6.5 million at the end of the third quarter.
• The all-in cost per gram of dry flower was $0.75 for the full year, compared to $0.36 in 2022, due to reduced agricultural output and changes in cultivation techniques.
• The net loss for 2023 was $17.9 million, a significant improvement from the $66.2 million loss in 2022.
• Adjusted EBITDA improved to $(12.4) million in 2023, compared to $(16.3) million in 2022.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong revenue growth in the cannabinoid segment, significant cost reductions, and the sale of the non-core business. However, there are still challenges related to profitability and market variability.

Positives

• Clever Leaves achieved a significant increase in cannabinoid revenue, demonstrating strong demand for its products.
• The company successfully reduced its operating expenses, indicating improved cost management.
• The sale of the non-cannabinoid business allows the company to focus on its core cannabinoid operations.
• The company improved its cash position, providing more financial stability.
• The company significantly increased its harvest of dry flower in Q4 2023 compared to the same period in 2022.
• The net loss was significantly reduced year-over-year, showing progress towards profitability.
• The company has secured Australian GMP certification for cannabis products.

Negatives

• The company experienced variability in the timing and issuance of Brazilian quotas.
• Order stoppages in Israel resulted from the current geopolitical conflict.
• The all-in cost per gram of dry flower increased for the full year 2023 compared to 2022.
• The company experienced a gross loss in Q4 2023, including inventory provisions.
• The company's cash balance decreased year-over-year.

Risks

• The company's ability to continue as a going concern is a risk.
• Maintaining the listing of securities on Nasdaq is a risk.
• The company faces risks related to implementing restructuring initiatives.
• There are uncertainties regarding future operating and financial performance and growth.
• The company's ability to execute its business plans and receive regulatory approvals is a risk.
• Global economic and business conditions, including geopolitical events, pose risks.
• Regulatory developments in key markets could impact the company.
• There is uncertainty with respect to the requirements applicable to certain cannabis products.
• Consumer, legislative, and regulatory sentiment regarding the company's products is a risk.
• The company faces risks related to product liability claims.
• Access to additional financing is a risk.
• The company's ability to remediate material weaknesses in its internal control over financial reporting is a risk.

Future Outlook

Clever Leaves remains focused on driving further capital preservation and operational efficiencies in 2024, concentrating on core international cannabinoid markets and streamlining Colombian production. They are also working towards developing inroads to the European markets.

Management Comments

• Andres Fajardo, CEO of Clever Leaves, stated that the company executed on strategic initiatives to refine commercial and production operations, as well as optimize capital efficiency and cost structure throughout 2023.
• Fajardo noted the continued support for cannabinoid products in Australia and Brazil, resulting in a 39% year-over-year increase in cannabinoid revenue.
• Fajardo highlighted the company's continued cost optimization efforts, driving year-over-year general and administrative expense reductions.
• Fajardo mentioned the company's focus on core international cannabinoid markets, Colombian production efficiencies, and efforts to preserve and improve cash liquidity.

Industry Context

This announcement reflects the ongoing challenges and opportunities in the global medical cannabis industry, with companies focusing on cost optimization, strategic market expansion, and regulatory compliance. Clever Leaves' focus on international markets and GMP certifications aligns with industry trends towards globalized supply chains and quality standards.

Comparison to Industry Standards

• Clever Leaves' 39% increase in cannabinoid revenue is a strong result compared to some competitors in the medical cannabis space, although specific comparisons are difficult without detailed competitor data.
• The company's focus on cost reduction is a common theme in the industry, as many companies are still working towards profitability.
• The sale of the non-cannabinoid business is a strategic move that aligns with the trend of companies focusing on core competencies.
• The company's GMP certifications are a key differentiator in the industry, as they demonstrate a commitment to quality and compliance.
• Compared to companies like Aurora Cannabis and Canopy Growth, who have also been focusing on cost reductions and strategic market exits, Clever Leaves appears to be making progress in streamlining operations and focusing on core markets.

Stakeholder Impact

• Shareholders may view the revenue growth and cost reductions positively.
• Employees may be impacted by the restructuring and focus on core operations.
• Customers in Australia and Brazil will benefit from the continued supply of cannabinoid products.
• Suppliers may be affected by the company's focus on core operations and cost optimization.
• Creditors may view the improved cash position and reduced losses positively.

Next Steps

• Clever Leaves will continue to focus on driving further capital preservation and operational efficiencies.
• The company will maintain its work on core international cannabinoid markets and Colombian production efficiencies.
• Clever Leaves will continue to work towards developing inroads to the European markets.

Key Dates

Keywords

cannabis, medical cannabis, cannabinoid, revenue, cost reduction, financial results, GMP certification, Colombia, Australia, Brazil, operating expenses, net loss, EBITDA